- Home
- IHT vs CANF Comparison
IHT vs CANF Comparison
Compare IHT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHT
- CANF
- Stock Information
- Founded
- IHT 1971
- CANF 1994
- Country
- IHT United States
- CANF Israel
- Employees
- IHT N/A
- CANF N/A
- Industry
- IHT Investment Bankers/Brokers/Service
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- IHT Finance
- CANF Health Care
- Exchange
- IHT Nasdaq
- CANF Nasdaq
- Market Cap
- IHT 18.0M
- CANF 14.4M
- IPO Year
- IHT N/A
- CANF N/A
- Fundamental
- Price
- IHT $2.28
- CANF $1.48
- Analyst Decision
- IHT
- CANF Strong Buy
- Analyst Count
- IHT 0
- CANF 2
- Target Price
- IHT N/A
- CANF $14.00
- AVG Volume (30 Days)
- IHT 2.5K
- CANF 1.2M
- Earning Date
- IHT 12-31-2024
- CANF 12-31-2024
- Dividend Yield
- IHT 0.88%
- CANF N/A
- EPS Growth
- IHT N/A
- CANF N/A
- EPS
- IHT N/A
- CANF N/A
- Revenue
- IHT $7,692,305.00
- CANF $667,000.00
- Revenue This Year
- IHT N/A
- CANF $409.56
- Revenue Next Year
- IHT N/A
- CANF N/A
- P/E Ratio
- IHT N/A
- CANF N/A
- Revenue Growth
- IHT 4.55
- CANF N/A
- 52 Week Low
- IHT $1.22
- CANF $1.29
- 52 Week High
- IHT $2.36
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- IHT 59.17
- CANF 35.58
- Support Level
- IHT $2.06
- CANF $1.30
- Resistance Level
- IHT $2.24
- CANF $1.72
- Average True Range (ATR)
- IHT 0.13
- CANF 0.18
- MACD
- IHT -0.00
- CANF -0.01
- Stochastic Oscillator
- IHT 100.00
- CANF 17.92
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).